Literature DB >> 3493255

Augmentation of growth hormone secretion during puberty: evidence for a pulse amplitude-modulated phenomenon.

N Mauras, R M Blizzard, K Link, M L Johnson, A D Rogol, J D Veldhuis.   

Abstract

The augmentation of GH secretion that occurs during puberty has been attributed to changes in sex steroid levels that enhance the frequency and amplitude of GH pulses. To investigate the specific GH pulse characteristics responsible for such augmentation we analyzed the serum GH concentration profiles of 10 boys in Tanner stages I-II of sexual development (group A; aged 10 5/12-15 1/12 yr) and compared their GH pulse characteristics with those of 5 boys at Tanner stages IV-V of development (group B; aged 14 8/12-15 1/12 yr). We also reanalyzed previously reported data from 5 prepubertal boys (group C; aged 13 6/12-15 5/12 yr) before and after 10 weeks of treatment with testosterone enanthate (100 mg/4 weeks, im). Using a pulse detection algorithm that constrains the false positive pulse detection rate to less than 5% (Cluster), we found that group B boys had a significantly higher mean serum GH pulse amplitude compared to group A boys (17.1 +/- 2.6 vs. 8.6 +/- 1.7 ng/mL; P = 0.012), but both groups had the same mean GH pulse frequency (group B, 5.4 +/- 0.5 pulses/24 h vs. group A, 5.5 +/- 0.4 pulses/24 h; P greater than 0.05). Similar changes were found in group C boys before and after testosterone therapy; there was no significant change in GH pulse frequency (6.6 +/- 0.9 before vs. 7.6 +/- 0.5 pulses/24 h after treatment; P greater than 0.05), but there was a significant increase in the GH pulse amplitude after therapy (6.8 +/- 1.6 before vs. 15.4 +/- 2.4 ng/mL after treatment; P = 0.04). When the 24-h GH concentration profiles were analyzed using a mathematically distinct method for the estimation of pulse amplitudes, namely the Fourier expansion time series, we confirmed a significant increase in GH pulse amplitude with later stages of puberty and androgen treatment. We conclude that the augmentation in GH secretion that occurs during either spontaneous puberty or exogenous testosterone therapy is an amplitude-modulated phenomenon, relatively independent of changes in pulse frequency. Such an effect may be secondary to the action of sex steroid hormones modulating either the responsivity of somatotrophs to endogenous GH-releasing hormone, the amount of GH-releasing hormone secreted, or the tonic inhibitory tone of somatostatin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3493255     DOI: 10.1210/jcem-64-3-596

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  35 in total

1.  The effect of training in male prepubertal and pubertal monozygotic twins.

Authors:  Apostolos Danis; Yannis Kyriazis; Vassilis Klissouras
Journal:  Eur J Appl Physiol       Date:  2003-03-14       Impact factor: 3.078

Review 2.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

Review 3.  Optimum use of growth hormone in children.

Authors:  Z Laron; O Butenandt
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

4.  Determinants of dual secretagogue drive of burst-like growth hormone secretion in premenopausal women studied under a selective estradiol clamp.

Authors:  Dana Erickson; Daniel M Keenan; Leon Farhy; Kristi Mielke; Cyril Y Bowers; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

Review 5.  Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

Authors:  J D Veldhuis; W S Evans; C Y Bowers; S Anderson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

Review 6.  Disturbance of growth hormone--insulin-like growth factor axis in uraemia. Implications for recombinant human growth hormone treatment.

Authors:  B Tönshoff; F Schaefer; O Mehls
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

7.  Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice.

Authors:  O Vidal; M K Lindberg; K Hollberg; D J Baylink; G Andersson; D B Lubahn; S Mohan; J A Gustafsson; C Ohlsson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

8.  Contribution of dose and frequency of administration to the therapeutic effect of growth hormone.

Authors:  P J Smith; P C Hindmarsh; C G Brook
Journal:  Arch Dis Child       Date:  1988-05       Impact factor: 3.791

9.  Skeletal maturation and hormonal levels after the menarche.

Authors:  E Porcu; S Venturoli; R Fabbri; R Paradisi; M Longhi; E Sganga; C Flamigni
Journal:  Arch Gynecol Obstet       Date:  1994       Impact factor: 2.344

10.  Aromatase and 5alpha-reductase inhibition during an exogenous testosterone clamp unveils selective sex steroid modulation of somatostatin and growth hormone secretagogue actions in healthy older men.

Authors:  Johannes D Veldhuis; Kristi L Mielke; Mihaela Cosma; Cacia Soares-Welch; Remberto Paulo; John M Miles; Cyril Y Bowers
Journal:  J Clin Endocrinol Metab       Date:  2008-12-16       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.